Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Community Acquired Pneumonia (CAP) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Community Acquired Pneumonia (CAP) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Community Acquired Pneumonia (CAP) Overall Market Size
2.1 Global Community Acquired Pneumonia (CAP) Market Size: 2021 VS 2028
2.2 Global Community Acquired Pneumonia (CAP) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Community Acquired Pneumonia (CAP) Players in Global Market
3.2 Top Global Community Acquired Pneumonia (CAP) Companies Ranked by Revenue
3.3 Global Community Acquired Pneumonia (CAP) Revenue by Companies
3.4 Top 3 and Top 5 Community Acquired Pneumonia (CAP) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Community Acquired Pneumonia (CAP) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Community Acquired Pneumonia (CAP) Players in Global Market
3.6.1 List of Global Tier 1 Community Acquired Pneumonia (CAP) Companies
3.6.2 List of Global Tier 2 and Tier 3 Community Acquired Pneumonia (CAP) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Community Acquired Pneumonia (CAP) Market Size Markets, 2021 & 2028
4.1.2 Chest X-ray/Radiography
4.1.3 Sputum Gram Stain and/or Culture
4.1.4 Blood Cultures
4.2 By Type - Global Community Acquired Pneumonia (CAP) Revenue & Forecasts
4.2.1 By Type - Global Community Acquired Pneumonia (CAP) Revenue, 2017-2022
4.2.2 By Type - Global Community Acquired Pneumonia (CAP) Revenue, 2023-2028
4.2.3 By Type - Global Community Acquired Pneumonia (CAP) Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Community Acquired Pneumonia (CAP) Market Size, 2021 & 2028
5.1.2 Hospitals and Clinics
5.1.3 Others
5.2 By Application - Global Community Acquired Pneumonia (CAP) Revenue & Forecasts
5.2.1 By Application - Global Community Acquired Pneumonia (CAP) Revenue, 2017-2022
5.2.2 By Application - Global Community Acquired Pneumonia (CAP) Revenue, 2023-2028
5.2.3 By Application - Global Community Acquired Pneumonia (CAP) Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Community Acquired Pneumonia (CAP) Market Size, 2021 & 2028
6.2 By Region - Global Community Acquired Pneumonia (CAP) Revenue & Forecasts
6.2.1 By Region - Global Community Acquired Pneumonia (CAP) Revenue, 2017-2022
6.2.2 By Region - Global Community Acquired Pneumonia (CAP) Revenue, 2023-2028
6.2.3 By Region - Global Community Acquired Pneumonia (CAP) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Community Acquired Pneumonia (CAP) Revenue, 2017-2028
6.3.2 US Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.3.3 Canada Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.3.4 Mexico Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Community Acquired Pneumonia (CAP) Revenue, 2017-2028
6.4.2 Germany Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4.3 France Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4.4 U.K. Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4.5 Italy Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4.6 Russia Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4.7 Nordic Countries Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.4.8 Benelux Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Community Acquired Pneumonia (CAP) Revenue, 2017-2028
6.5.2 China Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.5.3 Japan Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.5.4 South Korea Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.5.5 Southeast Asia Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.5.6 India Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Community Acquired Pneumonia (CAP) Revenue, 2017-2028
6.6.2 Brazil Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.6.3 Argentina Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Community Acquired Pneumonia (CAP) Revenue, 2017-2028
6.7.2 Turkey Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.7.3 Israel Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.7.4 Saudi Arabia Community Acquired Pneumonia (CAP) Market Size, 2017-2028
6.7.5 UAE Community Acquired Pneumonia (CAP) Market Size, 2017-2028
7 Players Profiles
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Community Acquired Pneumonia (CAP) Major Product Offerings
7.1.4 Pfizer Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.1.5 Pfizer Key News
7.2 Astrazeneca
7.2.1 Astrazeneca Corporate Summary
7.2.2 Astrazeneca Business Overview
7.2.3 Astrazeneca Community Acquired Pneumonia (CAP) Major Product Offerings
7.2.4 Astrazeneca Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.2.5 Astrazeneca Key News
7.3 Bioaegis Therapeutics
7.3.1 Bioaegis Therapeutics Corporate Summary
7.3.2 Bioaegis Therapeutics Business Overview
7.3.3 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Major Product Offerings
7.3.4 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.3.5 Bioaegis Therapeutics Key News
7.4 Biotest
7.4.1 Biotest Corporate Summary
7.4.2 Biotest Business Overview
7.4.3 Biotest Community Acquired Pneumonia (CAP) Major Product Offerings
7.4.4 Biotest Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.4.5 Biotest Key News
7.5 C10 Pharma
7.5.1 C10 Pharma Corporate Summary
7.5.2 C10 Pharma Business Overview
7.5.3 C10 Pharma Community Acquired Pneumonia (CAP) Major Product Offerings
7.5.4 C10 Pharma Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.5.5 C10 Pharma Key News
7.6 Kyorin Pharmaceutical
7.6.1 Kyorin Pharmaceutical Corporate Summary
7.6.2 Kyorin Pharmaceutical Business Overview
7.6.3 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Major Product Offerings
7.6.4 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.6.5 Kyorin Pharmaceutical Key News
7.7 Melinta Therapeutics
7.7.1 Melinta Therapeutics Corporate Summary
7.7.2 Melinta Therapeutics Business Overview
7.7.3 Melinta Therapeutics Community Acquired Pneumonia (CAP) Major Product Offerings
7.7.4 Melinta Therapeutics Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.7.5 Melinta Therapeutics Key News
7.8 Merck
7.8.1 Merck Corporate Summary
7.8.2 Merck Business Overview
7.8.3 Merck Community Acquired Pneumonia (CAP) Major Product Offerings
7.8.4 Merck Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.8.5 Merck Key News
7.9 Nabriva Therapeutics
7.9.1 Nabriva Therapeutics Corporate Summary
7.9.2 Nabriva Therapeutics Business Overview
7.9.3 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Major Product Offerings
7.9.4 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.9.5 Nabriva Therapeutics Key News
7.10 Paratek Pharmaceuticals
7.10.1 Paratek Pharmaceuticals Corporate Summary
7.10.2 Paratek Pharmaceuticals Business Overview
7.10.3 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Major Product Offerings
7.10.4 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Revenue in Global Market (2017-2022)
7.10.5 Paratek Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer